Ser272
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser272  -  RAD9A (human)

Site Information
LSDtDSHsQDLGsPE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447824
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 17 ) , electrophoretic mobility shift ( 16 , 17 ) , flow cytometry ( 4 ) , mass spectrometry ( 1 , 3 , 5 , 7 , 8 , 9 , 10 , 11 , 13 , 14 ) , mutation of modification site ( 4 , 6 , 15 , 16 , 17 ) , peptide sequencing ( 16 ) , phospho-antibody ( 2 , 4 , 6 , 12 , 15 , 16 , 17 ) , western blotting ( 2 , 4 , 6 , 12 , 15 )
Disease tissue studied:
ataxia-telangiectasia ( 12 , 15 ) , breast cancer ( 1 , 5 ) , colorectal cancer ( 6 ) , colorectal carcinoma ( 6 ) , leukemia ( 13 ) , chronic myelogenous leukemia ( 13 ) , lung cancer ( 3 ) , small-cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
ATM (human) ( 15 ) , ATR (human) ( 6 ) , DNAPK (human) ( 6 ) , MRE11A (human) ( 6 ) , NBS1 (human) ( 6 ) , RAD50 (human) ( 6 )
Putative in vivo kinases:
ATM (human) ( 6 , 12 , 15 , 17 )
Kinases, in vitro:
ATM (human) ( 17 )
Treatments:
camptothecin ( 6 ) , hydroxyurea ( 6 , 16 , 17 ) , ICRF-193 ( 12 ) , ionizing_radiation ( 4 , 6 , 12 , 15 , 16 , 17 ) , KU-55933 ( 6 ) , siRNA ( 6 ) , UV ( 6 , 14 , 16 , 17 )

Downstream Regulation
Effects of modification on RAD9A:
activity, induced ( 17 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 6 , 17 ) , DNA repair, induced ( 6 )

References 

1

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

2

Osorio-Zambrano WF, Davey S (2015) Chk1 Activation Protects Rad9A from Degradation as Part of a Positive Feedback Loop during Checkpoint Signalling. PLoS One 10, e0144434
26658951   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Kelly R, Davey SK (2013) Tousled-like kinase-dependent phosphorylation of rad9 plays a role in cell cycle progression and g2/m checkpoint exit. PLoS One 8, e85859
24376897   Curated Info

5

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

6

Shin MH, et al. (2012) ATM-dependent phosphorylation of the checkpoint clamp regulates repair pathways and maintains genomic stability. Cell Cycle 11, 1796-803
22453082   Curated Info

7

Mulhern D (2012) CST Curation Set: 14049; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

8

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

9

Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

10

Zhou J (2011) CST Curation Set: 11709; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

11

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

12

Greer Card DA, Sierant ML, Davey S (2010) Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition. J Biol Chem 285, 15653-61
20305300   Curated Info

13

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

14

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

15

St Onge RP, Besley BD, Pelley JL, Davey S (2003) A role for the phosphorylation of hRad9 in checkpoint signaling. J Biol Chem 278, 26620-8
12734188   Curated Info

16

Roos-Mattjus P, et al. (2003) Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. J Biol Chem 278, 24428-37
12709442   Curated Info

17

Chen MJ, et al. (2001) ATM-dependent phosphorylation of human Rad9 is required for ionizing radiation-induced checkpoint activation. J Biol Chem 276, 16580-6
11278446   Curated Info